GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Le résumé fourni par la source

(Cell 188, 5142–5156.e1–e23; September 18, 2025)In the original online version of the article, the predicted binding modes for compounds 15 and 21 were mislabeled as 21 and 15, respectively, in Figure 3C. The template and mutant constructs of β2AR were incorrectly referred to as ADRA2B instead of ADRB2 in the “method details.” In Figure S1C, the figure caption underreported the number of independent experiments (n = 4–10) and should read: “Data are shown as ligand-stimulated BRET mean ± SEM (n = 5–10 biologically independent experiments).” Two errors were also noted in Mendeley Data S14 and S21. Specifically, the error bars presented in subpanels C to F in Mendeley Data S14 are SEM, not SD, and the image depicting compound 21 on page S4 of Mendeley Data S21 is missing a fluorine in position 3 on the benzene ring. These items have now been corrected in the online version of the article, and the authors apologize for any confusion that this may have created. [Figure presented][Figure presented]

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.